Serum markers support disease-specific glial pathology in major depression

Schroeter, Matthias L.; Abdul‐Khaliq, Hashim; Krebs, Michaël; Diefenbacher, Albert; Blasig, Ingolf E.

doi:10.1016/j.jad.2008.03.005

Cited by 134 publications

(129 citation statements)

References 75 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…The results of this study are not directly supporting this hypothesis as the astro-and oligodendrocytic marker S100B was unaltered. Several studies have, however, reported increased serum S100B concentrations during episodes of mania and depression (MachadoVieira et al, 2002;Schroeter et al, 2002;Andreazza et al, 2007;Schroeter et al, 2008). A study of serum from euthymic bipolar patients, however, reported no differences in S100B, in line with the finding in the current study (Andreazza et al, 2007).…”

Section: Discussionsupporting

confidence: 86%

Elevated Concentrations of Neurofilament Light Chain in the Cerebrospinal Fluid of Bipolar Disorder Patients

Jakobsson

Bjerke

Ekman

et al. 2014

Neuropsychopharmacol

View full text Add to dashboard Cite

Bipolar disorder (BD) is characterized by mood swings between manic and depressive states. The etiology and pathogenesis of BD is unclear, but many of the affected cognitive domains, as well as neuroanatomical abnormalities, resemble symptoms and signs of small vessel disease. In small vessel disease, cerebrospinal fluid (CSF) markers reflecting damages in different cell types and subcellular structures of the brain have been established. Hence, we hypothesized that CSF markers related to small vessel disease may also be applicable as biomarkers for BD. To investigate this hypothesis, we sampled CSF from 133 patients with BD and 86 healthy controls. The concentrations of neurofilament light chain (NF-L), myelin basic protein (MBP), S100B, and heart-type fatty acid binding protein (H-FABP) were measured in CSF and analyzed in relation to diagnosis, clinical characteristics, and ongoing medications. Hereby we found an elevation of the marker of subcortical axonal damage, NF-L, in bipolar subjects. We also identified positive associations between NF-L and treatment with atypical antipsychotics, MBP and lamotrigine, and H-FABP and lithium. These findings indicate axonal damage as an underlying neuropathological component of bipolar disorder, although the clinical value of elevated NF-L remains to be validated in follow-up studies. The associations between current medications and CSF brain injury markers might aid in the understanding of both therapeutic and adverse effects of these drugs.

show abstract

Section: Discussionsupporting

confidence: 86%

Elevated Concentrations of Neurofilament Light Chain in the Cerebrospinal Fluid of Bipolar Disorder Patients

Jakobsson

Bjerke

Ekman

et al. 2014

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Thus, fluctuations in serum levels of BDNF and S100B seem to be state markers for major depression. This is supported by powerful meta-analyses including a very high number of subjects (Schroeter et al, 2008;Polyakova et al, 2015). NSE is a marker for neuronal injury.…”

Section: Introductionmentioning

confidence: 90%

First Evidence For Glial Pathology In Late Life Minor Depression: s100b Is Increased In Males With Minor Depression

et al. 2016

View full text Add to dashboard Cite

Minor depression is diagnosed when a patient suffers from 2 to 4 depressive symptoms for at least 2 weeks. Though minor depression is a widespread phenomenon, its pathophysiology has hardly been studied. To get a first insight into the pathophysiological mechanisms underlying this disorder we assessed serum levels of biomarkers for plasticity, glial and neuronal function: brain-derived neurotrophic factor (BDNF), S100B and neuron specific enolase (NSE). 27 subjects with minor depressive episode and 82 healthy subjects over 60 years of age were selected from the database of the Leipzig population-based study of civilization diseases (LIFE). Serum levels of BDNF, S100B and NSE were compared between groups, and correlated with age, body-mass index (BMI), and degree of white matter hyperintensities (score on Fazekas scale). S100B was significantly increased in males with minor depression in comparison to healthy males, whereas other biomarkers did not differ between groups (p = 0.10-0.66). NSE correlated with Fazekas score in patients with minor depression (r s = 0.436, p = 0.048) and in the whole sample (r s = 0.252, p = 0.019). S100B correlated with BMI (r s = 0.246, p = 0.031) and with age in healthy subjects (r s = 0.345, p = 0.002). Increased S100B in males with minor depression, without alterations in BDNF and NSE, supports the glial hypothesis of depression. Correlation between white matter hyperintensities and NSE underscores the vascular hypothesis of late life depression.

show abstract

“…In in vitro experiments, S100B exerts both detrimental and neurotrophic effects, depending on its concentration in brain tissues [3][4][5] . The plasma levels of S100B were recently found to be slightly increased [3] in psychiatric disorders such as schizophrenia [6][7][8][9][10][11] , major depression [12][13][14] , mania [15] and Alzheimer's disease [3] . A recent meta-analysis by Schroeter et al [14] revealed that S100B serum levels were consistently increased in acute major depressive or manic episodes and decreased during antidepressive treatment if clinical improvement was sufficient.…”

Section: Introductionmentioning

confidence: 99%

S100B Serum Levels and Word Memory Processing in Remitted Major Depression as Reflected by Brain Potentials

Zhang

Rothermundt²,

Peters³

et al. 2009

Neuropsychobiology

View full text Add to dashboard Cite

Objective: Memory processes, as reflected by ‘old/new’ effects of event-related potentials (ERPs), have been shown to be impaired in depressed patients. This variability might be partly explained by biological factors. S100B is a glial calcium-binding protein with neuroplastic properties; S100B serum levels have been shown to be increased in depressive patients. The pathophysiologic role of S100B in depression, however, is not yet sufficiently understood. Methods: In the present study, ERPs recorded in a visual continuous word recognition paradigm were therefore investigated in patients with remitted major depression in relation to S100B serum levels. Results: Patients with moderately increased S100B serum levels (n = 6) showed a normal old/new effect in contrast to a reduced old/new effect in patients with normal S100B levels (n = 6) compared to aged-matched controls. Conclusions: These findings provide evidence of an association between S100B levels and memory processes in patients with recurrent depression and further suggest a neuroprotective role of moderately increased S100B serum levels in the course of affective disorders.

show abstract

Serum markers support disease-specific glial pathology in major depression

Cited by 134 publications

References 75 publications

Elevated Concentrations of Neurofilament Light Chain in the Cerebrospinal Fluid of Bipolar Disorder Patients

Elevated Concentrations of Neurofilament Light Chain in the Cerebrospinal Fluid of Bipolar Disorder Patients

First Evidence For Glial Pathology In Late Life Minor Depression: s100b Is Increased In Males With Minor Depression

S100B Serum Levels and Word Memory Processing in Remitted Major Depression as Reflected by Brain Potentials

Contact Info

Product

Resources

About